Momordica Charantia lectin exhibits antitumor activity towards hepatocellular carcinoma Chris Zhiyi ZhangEvandro Fei FangJing-Ping Yun PRECLINICAL STUDIES 09 September 2014 Pages: 1 - 11
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer Bo Mi KuEun Hye JhoMyung-Ju Ahn PRECLINICAL STUDIES 25 October 2014 Pages: 12 - 21
Acetylamine derivative of diospyrin, a plant-derived binaphthylquinonoid, inhibits human colon cancer growth in Nod-Scid mice Sudipta HazraSubhalakshmi GhoshBanasri Hazra PRECLINICAL STUDIES 30 September 2014 Pages: 22 - 31
Identification of cellular and molecular factors determining the response of cancer cells to six ergot alkaloids Marco MrusekEan-Jeong SeoThomas Efferth PRECLINICAL STUDIES 25 October 2014 Pages: 32 - 44
Novel benzoxazines as inhibitors of angiogenesis Sara Al-RawiTerri Meehan-AndrewsJasim Al-Rawi PRECLINICAL STUDIES 23 October 2014 Pages: 45 - 52
Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer Alberta BergamoTina RiedelGianni Sava PRECLINICAL STUDIES 23 October 2014 Pages: 53 - 63
Selective ROS-dependent p53-associated anticancer effects of the hypoxoside derivative rooperol on human teratocarcinomal cancer stem-like cells Sarah Ali AzouaouFathi EmhemmedGuy Fuhrmann PRECLINICAL STUDIES 19 November 2014 Pages: 64 - 74
Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent Farid OuchaniAlbin JeanneJérôme Devy PRECLINICAL STUDIES 19 November 2014 Pages: 75 - 85
The marine natural product microsclerodermin A is a novel inhibitor of the nuclear factor kappa B and induces apoptosis in pancreatic cancer cells Esther A. GuzmánKelly MaersAmy E. Wright PRECLINICAL STUDIES 23 November 2014 Pages: 86 - 94
In vitro evaluation of a tetrahydroisoquinoline derivative as a steroid sulfatase inhibitor and a selective estrogen receptor modulator Charles OuelletÉtienne OuelletDonald Poirier PRECLINICAL STUDIES 21 November 2014 Pages: 95 - 103
4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents Pietro Di FazioSusanne LingelbachBernhard Biersack PRECLINICAL STUDIES 20 November 2014 Pages: 104 - 108
Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study Joal D. BeaneKayla F. GriffinUdo Rudloff PHASE I STUDIES 19 September 2014 Pages: 109 - 118
Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer Hirofumi MukaiToshiaki SaekiYasutsuna Sasaki PHASE I STUDIES Open access 23 September 2014 Pages: 119 - 127
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma Lipika GoyalRaymond C. WadlowAndrew X. Zhu PHASE I STUDIES 24 September 2014 Pages: 128 - 137
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer Jaafar BennounaMarion DeslandresJean-Pierre Delord PHASE I STUDIES 24 September 2014 Pages: 138 - 147
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors Robert M. JotteDaniel D. Von HoffRobert Ilaria Jr PHASE I STUDIES 28 September 2014 Pages: 148 - 158
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors Igor PuzanovJeffrey SosmanAlex A. Adjei PHASE I STUDIES Open access 08 October 2014 Pages: 159 - 168
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors Noelle K. LoConteAlbiruni R. A. RazakGlenn Liu PHASE I STUDIES 17 October 2014 Pages: 169 - 176
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer Gerald S. FalchookStacy MoulderRazelle Kurzrock PHASE I STUDIES 18 October 2014 Pages: 177 - 186
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer Johanna C. BendellSuzanne F. JonesHoward A. Burris PHASE I STUDIES 22 October 2014 Pages: 187 - 193
Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours Haruo IguchiTomohiro NishinaKatsuro Yagawa PHASE I STUDIES 25 October 2014 Pages: 194 - 200
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy Suzanne LeijenSjaak A. BurgersJan H. M. Schellens PHASE I STUDIES 25 October 2014 Pages: 201 - 214
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors Gerald S. FalchookJennifer J. WhelerRazelle Kurzrock PHASE I STUDIES 04 November 2014 Pages: 215 - 224
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors Nuttapong NgamphaiboonGrace K. DyAlex A. Adjei PHASE I STUDIES 05 November 2014 Pages: 225 - 232
Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas Anne-Charlotte DubbelmanHilde RosingJos H. Beijnen PHASE I STUDIES 08 November 2014 Pages: 233 - 240
A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma Jennifer J. KnoxRui QinCharles Erlichman PHASE II STUDIES 16 October 2014 Pages: 241 - 246
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma David SchiffSantosh KesariDavid Reardon PHASE II STUDIES 13 November 2014 Pages: 247 - 253
Successful treatment of Evans syndrome with Tacrolimus Samer TabchiColette HannaMarwan Ghosn SHORT REPORT 12 September 2014 Pages: 254 - 256
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients C. NarjozA. CessotB. Blanchet SHORT REPORT 25 October 2014 Pages: 257 - 268
Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab Jeeyun LeeYong Sang HongWon Ki Kang Erratum 20 September 2014 Pages: 269 - 270